AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01916447 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPT-11
Description: Escalating doses (30-minute infusion of 120-180 mg/m2/dose, based on tolerability), IV (in the vein) on Day 1 of each 14-day treatment cycle. Number of cycles: until at least one of the discontinuation criteria is met.
Study NCT01916447 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Dose (infusion of 5 mg/kg administered per site standard practice), IV (in the vein) on Day 1 of each 14-day treatment cycle. Number of cycles: until at least one of the discontinuation criteria is met.
Study NCT02280200 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AFO to improve outcomes
Description: Ankle foot orthoses (AFO) are light-weight, low profile carbon fiber devices that store and release energy during ambulation. The AFO, in combination with standard of care advice to walk more, will be used to determine if there is any improvement in PAD patient outcomes.
Study NCT00540982 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vinorelbine ditartrate
Description: Varying doses ranging from 30 mg/m2 to 7.5 mg/m2 will be administered based upon liver function
Study NCT00540982 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: high performance liquid chromatography
Description: Used to determine plasma concentrations of vinorelbine
Study NCT00540982 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: intracellular fluorescence polarization analysis
Description: Used to determine concentration of lidocaine metabolic capacity
Study NCT00540982 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: liquid chromatography
Description: Used to determine concentrations of vinorelbine and its metabolites
Study NCT00540982 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mass spectrometry
Description: Used to determine concentrations of vinorelbine and its metabolites
Study NCT00540982 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Determination of concentrations of vinorelbine and its metabolites
Study NCT03367676 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Trastuzumab is administered at a loading dose of 8 mg/kg IV followed by 6 mg/kg every 21 days for 4 cycles.
Study NCT03367676 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel 100mg/m2，d1，iv，q3w\*4
Study NCT03146819 — intervention group
Intervention type: DEVICE
Intervention: iTotal PS Knee Replacement System
Description: Total Knee Replacement systems (Patient Specific)
Study NCT03146819 — intervention group
Intervention type: DEVICE
Intervention: Off-the-Shelf Knee Replacement System
Description: Total Knee Replacement systems (Off-the-shelf)
Study NCT02983357 — intervention group
Intervention type: RADIATION
Intervention: CT, X-Ray
Description: 2 anterior-posterior (AP) radiographs of the glenohumeral joint, one in internal rotation and the other in external rotation, along with axillary lateral films, will be completed of the affected operated shoulder. Also, a computed tomographic scan without contrast performed of same shoulder.
Study NCT02983357 — intervention group
Intervention type: OTHER
Intervention: Physical assessment
Description: Physically evaluate for shoulder function and pain using American Shoulder Elbow Score (ASES) Constant score and the Simple Shoulder Test to obtain specific shoulder functional, motion,and strength outcomes.
Study NCT02983357 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: Rand Short Form Health Survey (Rand SF-36) which is a patient completed quality of life measurement
Study NCT04020822 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Guardian Sensor (3)
Description: Guardian Sensor (3) connected to Guardian Link (3) Transmitter and/or Guardian Connect Transmitter.
Study NCT04131452 — intervention group
Intervention type: OTHER
Intervention: Filling out the forms including IDAS-II, BAI, SF-36 and FSFI
Description: Participants will fill out certain validated forms including the expanded version of the inventory of depression and anxiety symptoms (IDAS-II), Beck Anxiety inventory (BAI), Short Form Survey (SF-36) and Female Sexual Function Index (FSFI).
Study NCT00270205 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LC002 standard vaccination
Description: 0.1 mg DNA/participant, 0.8 ml total administered subcutaneously
Study NCT00270205 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LC002 high-dose vaccination
Description: 0.4 mg DNA/participant, 3.2 ml total administered subcutaneously
Study NCT00270205 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LC002 placebo vaccination
Description: Placebo vaccination administered subcutaneously
Study NCT02346240 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Certolizumab Pegol
Description: * Active Substance: Certolizumab Pegol~* Pharmaceutical Form: Solution for injection in pre-filled syringe~* Concentration: 200 mg/ mL~* Route of Administration: Subcutaneous use
Study NCT04543747 — intervention group
Intervention type: DEVICE
Intervention: HeartWare Ventricular Assist Device
Description: The Medtronic HVAD® System is comprised of three major components: the HVAD Pump with inflow and outflow conduits, a Controller and power sources. In addition to these components, the system includes a Monitor, Battery Charger, AC and DC power adapters, and a Carrying Case. The HVAD® System is indicated for hemodynamic support in patients with advanced, refractory left ventricular heart failure; either as a bridge to cardiac transplantation (BTT), myocardial recovery, or as destination therapy (DT) in patients for whom subsequent transplantation is not planned.
Study NCT03903575 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: En masse anterior teeth retraction
Description: After extraction of the four premolars the posterior teeth will be tied-together and the six anterior teeth will be retracted by sliding mechanics.
Study NCT03903575 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Two-Step Retraction
Description: After extraction of the four premolars the posterior teeth will be tied-together and the canines will be retracted by sliding mechanics. After the distalization of the canines they will be tied to the posterior teeth and the incisors will be retracted by sliding mechanics.
Study NCT02764606 — intervention group
Intervention type: BIOLOGICAL
Intervention: Serum and plasma samples
Description: Serum and plasma are collected at time of diagnosis, after surgery, and at time of progression to evaluate the value of new serum markers to predict the occurrence of metastases.
Study NCT02346240 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Etanercept
Description: * Active Substance: Etanercept~* Pharmaceutical Form: Solution for injection in pre-filled syringe~* Concentration: 50 mg / mL~* Route of Administration: Subcutaneous use
Study NCT02346240 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: * Active Substance: Placebo~* Pharmaceutical Form: Solution for injection in pre-filled syringe~* Concentration: 0.9 % saline~* Route of Administration: Subcutaneous use
Study NCT06514365 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPACK block with Bupivacaine 0.25% with adrenaline
Description: The iPACK in performed in the popliteal fossa about 1 finger breath above the patella, ecoguided. That aims to anesthetize the articular branches to the posterior aspect of the knee in the popliteal region.
Study NCT06514365 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IPACK block with Bupivacaine 0.25% with adrenaline
Description: The iPACK in performed in the popliteal fossa about 1 finger breath above the patella, ecoguided. That aims to anesthetize the articular branches to the posterior aspect of the knee in the popliteal region.
Study NCT02314130 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary therapy
Description: A enteral diet formulation was developed to meet dietary requirements of adult patients. The formulation was standarized in household measures so that caregivers would prepare it and delivered it at the patients' home. Anthropometric measurements and blood samples were taken at baseline and at the end of the intervention which lasted four months.
Study NCT01012531 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Subcutaneous injections with highly polymerized allergen extract
Description: cluster schedule
Study NCT01012531 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Subcutaneous injection with placebo
Description: cluster schedule
Study NCT04088617 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ketone monoester
Description: Acute ingestion of (R)-3-hydroxybutyl (R)-3-hydroxybutyrate prior a 2-hour high carbohydrate mixed meal tolerance test.
Study NCT04088617 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Acute ingestion of a taste-matched placebo prior a 2-hour high carbohydrate mixed meal tolerance test.
Study NCT00398476 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluticasone propionate (FP)
Description: 200 micrograms (mcg); an aqueous suspension of microfine FP
Study NCT00398476 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluticasone furoate (FF)
Description: 110 mcg; an aqueous suspension containing 0.05% w/w of micronized FF
Study NCT00333437 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Study NCT02131753 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Cladribine s.c. injection, HCL treatment
Description: Patients with hairy cell leukemia and the need for treatment are given cladribine 0.14 mg/kg for 5 consecutive days as a s. c bolus injection
Study NCT02017782 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dust
Description: Dust (250-300µg/m3),
Study NCT02017782 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dust
Description: Dust (250-300µg/m3),
Study NCT02017782 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ozone
Description: (0,1ppm ozone),
Study NCT02017782 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ozone
Description: (0,1ppm ozone),
Study NCT02017782 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dust and Ozone
Description: Active Dust (250-300 ug/m3)+Ozone(0,1ppm)
Study NCT02017782 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (Filtered air)
Description: Placebo treatment (Filtered air \<20 ug/m3)
Study NCT00220311 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate (Fludara)
Description: 6 cycles (1 cycle: 5 treatment days every 28 days)
Study NCT04524351 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Posiphen
Description: Solid oral dosage form, capsule
Study NCT04524351 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Solid oral dosage form, capsule
Study NCT01869231 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: olive oil
Study NCT01869231 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: olive oil and chewing gum
Study NCT01869231 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: chewing gum
Study NCT01869231 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: water
Study NCT00123188 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound and Biopsy
Description: Transvaginal ultrasound and Endometrial Biopsy
Study NCT05371262 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levothyroxin
Description: Congenital hypothyroidism children received two different doses of levothyroxin within the recommended range to evaluate any differences in long-term outcomes.
Study NCT00594581 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Juvista (avotermin) plus placebo, standard-care (within-subject controls)
Description: Intradermal Juvista (avotermin) at 50ng or 200ng per 100μl per linear cm of wound margin
Study NCT02780206 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stable isotope amino acid infusion
Description: such as glycerol, D2O, tyrosine, phenylalanine, glucose, arginine, and citrulline
Study NCT02468973 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Life style counseling
Description: Life style counseling for chronic patients by medical students
Study NCT00846573 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperpolarized Helium-3
Description: Patients will be required to breath in individual 1 liter bags of gas while in an MRI to produce lung images. These bags of gas are each made up of 333mL of Helium-3 gas and 667mL of Nitrogen. Three bags will be administered to acquire three different scans.
Study NCT00784004 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Breathing Patterns
Description: All subjects will breathe in four different breathing patterns which are provided by specific masks. Patterns are as the following:~1. Breathing in through the nose only and out through the mouth only~2. Breathing in through the mouth only and out through the nose only~3. Breathing in and out through the nose only~4. Breathing in and out through the mouth only
Study NCT01189162 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NIMV with SLE ventilator vs HFNC via Vapotherm
Description: Nasal respiratory support for RDS
Study NCT00738972 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: valsartan
Description: 80 mg valsartan. Duration: 12 months. Tablets
Study NCT00738972 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: valsartan
Description: 80 mg valsartan. Duration: 12 months. Tablets
Study NCT00738972 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pravastatin
Description: 40 mg pravastatin. Duration: 12 months. Tablets
Study NCT00738972 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: simvastatin
Description: 40 mg simvastatin. Duration: 12 months. Tablets
Study NCT00738972 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ezetimibe (+) simvastatin
Description: ezetimibe (+) simvastatin 10/40 mg. Duration: 12 months. Tablets
Study NCT01335958 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DMUC5754A
Description: Escalating intravenous dose
Study NCT04688671 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ETX-018810
Description: Study Drug
Study NCT04688671 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo
Study NCT02436161 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Care management program PROMIC
Description: intensive coaching intervention to optimize care and prevent readmissions, using educational selfcare and worsening symptoms recognition by patients and carers
Study NCT02788435 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Absolute Voice Rest
Description: Patients will be instructed to not use their voice and minimize any voice-use activities such as coughing or throat-clearing for a period of 7 days following surgery.
Study NCT04941820 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: clinical pharmacist intervention
Description: clinical pharmacist intervention
Study NCT03751501 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Indocyanine green-Guided Targeted Laser photocoagulation
Description: Detection of macro-aneurysms by ICG angiography, laser photocoagulation and optional post-laser verification of the effectiveness of the photothrombosis by OCT.
Study NCT03751501 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham laser
Description: Therapeutic procedure used in ophthalmology
Study NCT01736592 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Long term follow up in all patients who received SAR422459 in previous study TDU13583
Description: Blood draw for the laboratory assessment
Study NCT02441010 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: meridian therapy instrument
Description: The meridian therapy instrument are widely used to improve the physical and relieve fatigue and pain in many hospitals by the field-effect.
Study NCT02441010 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: health information push technology
Description: The health information push technology regularly send health information on the measurements of body weight control and the improvement of a healthy lifestyle.
Study NCT02441010 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: health information push technology
Description: The health information push technology regularly send health information on the measurements of body weight control and the improvement of a healthy lifestyle.
Study NCT02441010 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: health information push technology
Description: The health information push technology regularly send health information on the measurements of body weight control and the improvement of a healthy lifestyle.
Study NCT02441010 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: monitoring device
Description: The monitoring device is used to monitor a person's blood pressure, blood glucose, oxygen saturation, body weight, and energy consumption by Bluetooth Wireless technology.
Study NCT02441010 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: monitoring device
Description: The monitoring device is used to monitor a person's blood pressure, blood glucose, oxygen saturation, body weight, and energy consumption by Bluetooth Wireless technology.
Study NCT02441010 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: monitoring device
Description: The monitoring device is used to monitor a person's blood pressure, blood glucose, oxygen saturation, body weight, and energy consumption by Bluetooth Wireless technology.
Study NCT00839358 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: albumin
Description: albumine 40 g every 15 days
Study NCT00839358 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: albumin
Description: albumine 40 g every 15 days
Study NCT00839358 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midodrine
Description: Midodrine 5mg/8 hs, can be increase up to 8mg/8hs if there is a lack of increase in at least 10mmHg in mean arterial pressure after 15 days of treatment.
Study NCT00839358 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: saline solution
Study NCT00634946 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SI-6603
Description: SI-6603 is administrated into the nucleus pulposus of an intervertebral disc.
Study NCT00634946 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is administrated into the nucleus pulposus of an intervertebral disc.
Study NCT03983980 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tapinarof
Description: Tapinarof cream, 1%, applied once daily
Study NCT03983980 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Cream
Description: Vehicle cream applied once daily
Study NCT02766270 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: RT with daily temozolomide (75 mg/m2/day, 7 days/week for up to 7 weeks) and adjuvant temozolomide (150-200 mg/m2 PO QD for 5 days, repeats every 28 days for up to 12 courses).
Study NCT02766270 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Study NCT02766270 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy
Study NCT02084225 — intervention group
Intervention type: PROCEDURE
Intervention: ultrasound guided regional nerve block
Description: participants were the physicians performing the procedure
Study NCT03901313 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A - 400 mg Fasting
Description: Single oral 400 mg (2 × 200 mg capsules) dose of pexidartinib in the morning under fasting conditions
Study NCT03901313 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B - 400 mg Fed
Description: Single oral 400 mg (2 × 200 mg capsules) dose of pexidartinib in the morning within 30 minutes (min) after a low-fat standard breakfast meal
Study NCT03374774 — intervention group
Intervention type: DRUG
Intervention: BIAsp 30
Description: Participants will receive commercially available BIAsp 30 according to routine clinical practice. The physician will determine the starting dose and any potential later change to the dose.
Study NCT03901313 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C - 200 mg Fed
Description: Single oral 200 mg (1 × 200 mg capsule) dose of pexidartinib in the morning within 30 min after a low-fat standard breakfast meal
Study NCT00741000 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cervical Stairstep
Description: Cervical low force mobilization procedure.
Study NCT03275493 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19 CAR-T cells
Description: Express a Second Generation 4-1BB: CD19 CAR-T cells
Study NCT03275493 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19 CAR-T cells with CRS suppression technology
Description: Express a Second Generation 4-1BB:CD19 CAR-T cells with CRS suppression technology
Study NCT02271633 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Sodium nitrate
Study NCT02627690 — intervention group
Intervention type: OTHER
Intervention: islet transplanted
Description: islet transplantation